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There is an utmost necessity of developing novel biomarkers of depression that result 
in a more efficacious use of current antidepressant drugs. The present report reviews 
and discusses a recent series of experiments that focused on analysis of membrane 
protein clustering in peripheral lymphocytes as putative biomarkers of therapeutic 
efficacy for major depressive disorder. This review recapitulates how the ideas were 
originated, and the main findings demonstrated that analysis of serotonin transporter 
and serotonin 2 A receptor clustering in peripheral lymphocytes of naïve depression 
patients resulted in a discrimination of two subpopulations of depressed patients that 
showed a differential response upon 8 weeks of antidepressant treatment. The paper 
also reviews the usefulness of animal models of depression for an initial evaluation of 
membrane protein clustering in lymphocytes, which provides a screening tool to 
determine additional proteins to be further evaluated in depression patients. Finally, the 
present review provides a brief discussion of the general field of biomarkers of depression 
in relation to therapeutic outcomes and suggests additional ideas to provide extra value 
to the reviewed studies.
Keywords: biomarkers, depression, membrane protein clustering, therapeutic efficacy, antidepressants
CLINICAL INTEREST AND GENERAL APPROACHES FOR 
DEVELOPING NOVEL BIOMARKERS OF DEPRESSION
There is a pressing necessity to provide a better way for diagnosis, prognosis, and therapeutic 
treatment of psychiatric disorders. This is because in contrast to other medical specialties, 
psychiatry has lacked clear biological indicators (i.e., biomarkers) to help guide a proper 
diagnosis or prognosis or to ascertain the best therapeutic approach for individuals suffering 
mental disorders (for a general review of the neurobiology, physiopathology, and treatment 
of depression, see Otte et  al., 2016). This is of particular interest in the context of major 
depressive disorder (MDD) when considering that, although antidepressants are clearly 
efficacious to treat MDD (Cipriani et  al., 2018), a high percentage of patients fail to show 
a proper therapeutic response upon the first antidepressant treatment (Rush et  al., 2006). 
Accordingly, there has been an exponential increase in the number of publications focusing 
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on biomarkers of depression (almost 1,400 hits when searching 
for the term “biomarkers of depression” in the past 3 years 
in a recent PubMed search) and on biomarkers of antidepressant 
response (almost 200 hits when searching for the term 
“biomarkers of antidepressant response” in the past 3 years 
in a recent PubMed search). Although this blooming of 
publications indicates a keen interest by researchers in evaluating 
the efficacy of multiple biomarkers of depression, it seems 
that most of these biomarkers may not be  specific for MDD, 
and at the same time, there is a need of additional studies 
and clinical trials to validate the efficacy of these putative 
biomarkers (Quevedo and Yatham, 2018).
Current approaches to the discovery of novel biomarkers 
of diagnosis and/or therapeutic efficacy for MDD are mostly 
based on technological advances in neuroimaging or on the 
use of “Omics” technologies (i.e., genomics or other “Omics” 
approaches primarily used to define peripheral biomarkers of 
MDD) (see Gururajan et  al., 2016; Voegeli et  al., 2017; Busch 
and Menke, 2018). Recently, a series of systematic reviews 
have evaluated the effectiveness of multiple biomarkers of 
depression using genomics (Menezes et  al., 2019), epigenomics 
(Goud Alladi et  al., 2018), metabolomics (MacDonald et  al., 
2018), antidepressant pharmacologic treatment response (Voegeli 
et al., 2017), inflammatory biomarkers (Smith et al., 2018; Yang 
et  al., 2018), and neuroimaging biomarkers (Drago et  al., 2018; 
Levy et  al., 2019; Suh et  al., 2019).
Hypotheses-based approaches can also help to define novel 
biomarkers of depression and complement the information 
obtained from neuroimaging and “Omics” studies, with the final 
purpose of finding specific combinations of biomarkers (including 
“Omics,” neuroimaging, and hypotheses-based approaches) that 
can be  translated to the clinical and public health settings. In 
fact, some of the most replicated studies on biomarkers of 
depression are based on hypotheses-based approaches, such as 
alterations on serotonin transporter (SERT) binding in platelets 
or alterations in serum proinflammatory cytokines that may 
relate to specific inflammatory events underlying the 
pathophysiology of depression (reviewed in Gadad et  al., 2018).
Following that line of thinking, during the past few years, 
we  carried out an experimental approach to develop and test 
the hypothesis that alterations in the patterns of membrane protein 
clustering in peripheral lymphocytes can predict the therapeutic 
outcomes of psychopharmacological treatment in MDD. The 
present scientific review summarizes and discusses our findings, 
providing a proper context on how the studies were developed 
and points out toward additional experimental approaches designed 
for the validation and clinical translation of this approach.
DEVELOPMENT OF THE HYPOTHESIS 
THAT ALTERATIONS IN MEMBRANE 
PROTEIN CLUSTERING MAY BE  A 
PUTATIVE BIOMARKER OF MDD
During the second half of the 1990s, a series of reports from 
the laboratory of Drs. Erminio Costa and Alessandro Guidotti 
(University of Illinois at Chicago) provided the first 
demonstrations that the extracellular matrix protein reelin was 
heavily downregulated (about 50%) in multiple brain areas 
from schizophrenia post-mortem brain samples (Impagnatiello 
et  al., 1998) and in the cerebral cortex of bipolar patients 
with psychotic episodes (Guidotti et  al., 2000). These findings 
were followed by other laboratories that not only were able 
to replicate them but also demonstrated a downregulation of 
reelin levels in the hippocampus of schizophrenia, bipolar 
disorder, and major depression (Fatemi et  al., 2000).
Reelin is an extracellular matrix protein involved in 
developmental regulation of neuronal migration and in regulation 
of neural plasticity in the adult brain, which (as mentioned 
above) is downregulated in multiple psychiatric disorders (see 
Ishii et  al., 2016, as a review). Reelin primarily binds to the 
membrane receptors apolipoprotein receptor 2 and the very 
low density lipoprotein receptor in a heterodimeric combination 
and brings about the phosphorylation of the cytoplasmic adaptor 
protein DAB1, resulting in the activation of multiple signaling 
pathways resulting in the control of neural migration and 
cortical layer formation, promotion of protein translation, 
dendrite outgrowth and development of dendritic spines, and 
in regulation of glutamatergic synaptic plasticity (reviewed in 
Lee and D’Arcangelo, 2016).
From there on, studies focusing on the origin of reelin 
downregulation observed in psychiatric disorders (primarily 
in schizophrenia) pointed toward epigenetic alterations involving 
a hypermethylation of CpG islands in the reelin gene promoter 
as the cause of brain reelin deficits (recently reviewed in 
Guidotti et  al., 2016). At the same time, studies on animal 
models of depression provided numerous evidences that reelin 
downregulation in the subgranular zone of the dentate gyrus 
may affect the maturation of dentate newborn neurons (Lussier 
et al., 2009, 2013a) and dysregulate the glutamatergic-GABAergic 
systems crosstalk in limbic brain areas (Lussier et  al., 2013b). 
These alterations could be  reversed by conventional 
antidepressants (Fenton et  al., 2015) or by anti-inflammatory 
drugs with an antidepressant effect such as etanercept (Brymer 
et  al., 2018). Reelin haploinsufficient heterozygous reeler mice 
show some subtle alterations in neurochemistry and behavior, 
but otherwise are almost indistinguishable from wild-type mice; 
however, we  have found that these animals are extremely 
susceptible to the depressogenic effects of repeated subcutaneous 
injections of the stress hormone corticosterone and show 
depressive-like behavioral paradigms at corticosterone doses 
that fail to induce such behaviors in wild-type mice, which 
prompted us to consider reelin downregulation as a putative 
vulnerability factor for depression (Lussier et  al., 2011). In 
summary, all these studies indicated a possible important role 
for reelin in the pathophysiology of depression (reviewed in 
Caruncho et  al., 2016).
Concomitantly, other reports provided evidence indicating 
that reelin induces protein translation in synaptosome preparations 
(Dong et  al., 2003), increases the number and clustering of 
synaptosomal membrane proteins (Caruncho et  al., 2004), and 
promotes the clustering of the canonical reelin receptors ApoER2 
and VLDLR (Strasser et  al., 2004). For recent reviews of the 
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canonical and non-canonical reelin signaling pathways, see 
Bock and May (2016) and Lee and D’Arcangelo (2016).
Reelin is also expressed in blood plasma (Smalheiser 
et  al., 2000) where it is secreted by hepatocytes (Smalheiser 
et  al., 2000) and platelets (Tseng et  al., 2010), and plasma 
reelin levels are also altered in neuropsychiatric disorders 
(Fatemi et  al., 2001).
ALTERATIONS IN SEROTONIN 
TRANSPORTER (SERT) AND 
SEROTONIN RECEPTOR 2A (5HT2A) 
PERIPHERAL LYMPHOCYTES FROM 
ANIMALS WITH REELIN DEFICITS
The observations of reelin alterations in depression summarized 
above are the evidence that reelin induces membrane protein 
clustering (Dong et  al., 2003; Caruncho et  al., 2004), the 
finding that animals with reelin deficits (i.e., heterozygous 
reeler mice) are quite susceptible to the depressogenic effects 
of corticosterone (Lussier et  al., 2011), and the demonstration 
of reelin expression in blood plasma and its alterations in 
psychiatric disorders (Smalheiser et  al., 2000; Fatemi et  al., 
2001), prompted us to evaluate the possibility that animals 
expressing low reelin levels (such as heterozygous reeler mice) 
might show alterations in membrane protein clustering in 
peripheral blood cells.
We primarily centered our studies on analyzing the patterns 
of membrane clustering of two proteins pertaining serotonergic 
neurotransmission (SERT and 5HT2A) that are also expressed 
in lymphocytes and may be  involved in the regulation of 
inflammatory processes (recently reviewed by Wu et  al., 2018; 
also see Ahern, 2011). Alterations in SERT and 5HT2A are 
directly involved in the pathophysiology of depression and 
represent some of the targets of antidepressant medication, 
which is not surprising when considering the essential roles 
that the serotonergic system plays in the regulation of behavioral 
patterns directly affected in depression, such as mood, emotion, 
or sleep (for a recent review of the serotonergic hypothesis 
of depression, see Fakboury, 2016).
Our studies analyzing the pattern of membrane clustering 
of the serotonin transporter protein (SERT) in peripheral 
lymphocytes from heterozygous reeler mice, null reeler mice, 
and wild-type mice showed a patchy pattern of expression of 
SERT immunolabeling in lymphocyte membranes that becomes 
disrupted in animals with reelin deficits (Rivera-Baltanas et  al., 
2010). In fact, heterozygous reeler mice showed a significant 
increase in SERT cluster size, while in null reeler mice SERT 
immunolabeling was mostly evidenced as a diffuse staining and 
was difficult to demonstrate well-detailed patches (Rivera-Baltanas 
et  al., 2010). A schematic representation of alterations in SERT 
clustering in reeler mice lymphocytes is illustrated in Figure 1A.
Additionally, we  also evaluated possibly alterations in SERT 
and 5HT2A protein clustering in the repeated-corticosterone 
model of depression (Romay-Tallon et  al., 2018). This is a 
A
B
FIGURE 1 | Schematic representation of serotonin transporter (SERT) clusters in the plasma membrane of one representative lymphocyte in reeler mice (A) and  
in rats treated with corticosterone (B). Note that heterozygous reeler mice (Reln +/−) have an increase in SERT cluster number and size in comparison to  
wild-type mice (Reln +/+) and that homozygous reeler mice (Reln −/−) show much larger clusters that sometimes are difficult to differentiate [see Panel (A), and 
Rivera-Baltanas et al., 2010]. After repeated-corticosterone treatment, a well-defined animal model of depression, SERT clusters also appear to increase in  
size [see Panel (B), and Romay-Tallon et al., 2018].
Caruncho et al. Membrane Protein Clustering in Major Depression
Frontiers in Pharmacology | www.frontiersin.org 4 March 2019 | Volume 10 | Article 190
well-characterized animal model of depression (see Sterner and 
Kalynchuk, 2010, as a review) that we  have used in many of 
our studies pertaining reelin and depression (see above). 
We  found that repeated-corticosterone induced an increase in 
cluster size but not in cluster number for both SERT and 
5HT2A (Romay-Tallon et al., 2018). A schematic representation 
of alterations in SERT clustering in lymphocytes from animals 
treated with corticosterone is illustrated in Figure 1B.
The results of these studies, together with evidence of 
alterations in SERT binding in lymphocytes of depression 
patients (Urbina et  al., 1999; Lima and Urbina, 2002; Lima 
et  al., 2005; Pena et  al., 2005), brought us to develop the idea 
that perhaps the pattern of SERT clustering in lymphocytes 
might be  disrupted in depression patients and if so to study 
if those alterations correlate with scores on psychological scales.
ALTERATIONS IN SERT AND 
SEROTONIN 2A RECEPTOR (5HT2A) IN 
PERIPHERAL LYMPHOCYTES FROM 
DEPRESSION PATIENTS
We hypothesized that in naïve depression patients (i.e., patients 
who had not taken antidepressants at least for several months) 
the pattern of SERT clustering in lymphocytes would follow 
the lines of that observed in heterozygous reeler mice (i.e., the 
average SERT cluster size would be larger in depression patients 
than in normal controls) and that response to antidepressant 
medication would be  followed by a reversal of the alterations 
in the pattern of SERT clustering. Our findings generally showed 
that this was the case (i.e., naïve depression patients showed 
a similar number of SERT clusters per lymphocytes but they 
were of a larger size than those observed in samples from 
control non-psychiatric patients, for example, the average size 
of SERT clusters in the control population was about 0.11 and 
0.14  μm2 for naïve depression patients). However, the analysis 
of the distribution of SERT cluster size allowed us to differentiate 
two subpopulations of naïve depression patients that we named 
D-I and D-II, the D-I subpopulation represented about ¾ of 
the patients and showed more than 40% of SERT clusters being 
between 0.05 and 0.010  μm2 (the modal peak of cluster size), 
while the DII subpopulation showed around 25% of SERT 
clusters between 0.05 and 0.010  μm2 (Rivera-Baltanas et  al., 
2012). Although we  thought that these two subpopulations 
perhaps might reflect differential scores in psychological scales 
(i.e., in the Hamilton Depression Rating Scale, HDRS), when 
we  proceeded to check the scores we  observed that this was 
not the case, so that naïve depression D-I and D-II patients 
had similar HDRS scores (Rivera-Baltanas et  al., 2012).
Interestingly, upon 8 weeks of psychopharmacological 
treatment, there was a differential response between D-I and 
D-II patients, as about half D-I patients showed no-response 
or a partial response to antidepressant medication, while the 
whole group of D-II patients responded to treatment and 75% 
of them showed remission of symptoms (see Table 1, and 
also Rivera-Baltanas et  al., 2012, 2014, 2015). When analyzing 
the patterns of SERT clustering in lymphocytes after treatment, 
we found a significant increase in the number of SERT clusters 
within the size modal peak and a general increase in SERT 
cluster number in D-II patients, while there were no observable 
changes in the pattern of SERT clusters in D-I patients. A 
schematic representation of alterations in SERT clustering in 
lymphocytes from patients with depression is illustrated in 
Figure 2. In addition, the changes observed in D-II patients 
correlated with the amelioration of depression symptoms in 
these patients. These findings allowed us to suggest that analysis 
of the pattern of SERT protein clustering in lymphocytes could 
be  considered a putative biomarker of therapeutic efficacy in 
MDD (Rivera-Baltanas et al., 2012) and prompted us to analyze 
the pattern of SERT clustering in relation to additional 
psychological scales like Self-Assessment Anhedonia Scale (SAAS) 
(Olivares et al., 2005; Rivera-Baltanas et al., 2015) and to study 
possible alterations in the pattern of clustering of other proteins 
like 5HT2A receptor (Rivera-Baltanas et  al., 2014).
We focused on the study of the patterns of SERT clustering 
in depression patients in relation to a scale that measures 
anhedonia symptoms, because anhedonia is not only considered 
a key symptom of depression (APA, 2013) but is also 
conceptualized as a specific endophenotype of MDD (Pizzagalli, 
2014) and a predictor of treatment response (Spijker et  al., 
2001). The use of the SAAS scale to provide a possible 
correlation between anhedonia scores and SERT clusters was 
also motivated by the issue that the HDRS does not properly 
evaluate anhedonia symptoms (Berrios and Olivares, 1995; 
Olivares and Berrios, 1998). When we  evaluated the SAAS 
scores of D-I and D-II naïve depression patients, we  did not 
found any difference between the two groups (Rivera-Baltanas 
et  al., 2015). However, the post-treatment analysis evidenced 
differences in response between the D-I and D-II groups 
that were higher than those observed in the SERT-HDRS 
study, as the population of treated D-I patients did not improve 
at all SAAS scores, while D-II patients showed a remarkable 
improvement after 8 weeks of psychopharmacological treatment 
(Rivera-Baltanas et  al., 2015). These findings may have some 
implications in developing proper strategies for the treatment 
TABLE 1 | Differential improvement in scores in the Hamilton Depression Rating 
Scale (HDRS) passed to D-I and D-II patients after 8 weeks of antidepressant 
treatment.
HDRS after 
treatment
Non-responders 
and partial 
responders (%)
Responders 
without 
remission (%)
Remission of 
symptoms (%)
Overall depression 36 32 32
D-I 45 33 22
D-II 0 25 75
Non-responders: HDRS scores improvement of less than 25%.
Partial responders: HDRS scores improvement between 25 and 50%.
Responders without remission: HDRS scores improvement of more than 50%, but 
absolute value of 7 or more.
Remission of symptoms: HDRS scores improvement of more than 50%, and absolute 
value below 7.
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of anhedonia symptoms in MDD, as anhedonia seems to 
be  particularly refractory to treatment with current first- 
line antidepressant drugs (Shelton and Tomarken, 2001;  
Nutt et  al., 2007; McCabe et  al., 2009).
In a follow-up study, we  studied possible alterations in 
the pattern on 5HT2A receptor clustering in lymphocytes 
in MDD (Rivera-Baltanas et al., 2014). We analyzed alterations 
in 5HT2A clustering in samples from a subset of the same 
population that we  studied for SERT clustering (see above). 
We  were surprised to find that measurements of 5HT2A 
clustering patterns in lymphocytes from naive MDD patients 
not only allowed us to again differentiate two patient 
subpopulations according to the distribution of 5HT2A cluster 
size, but that the same patients who were characterized as 
D-I and D-II when studying SERT clustering parameters 
(see above) were similarly shown as D-I or D-II when 
analyzing the characteristics of 5HT2A clusters and logically 
gave rise to a similar differential response to treatment 
(Rivera-Baltanas et  al., 2014). In fact, these data made us 
think that perhaps there would be  a general disturbance in 
membrane protein clustering in lymphocytes that may 
be  operative in depression. Although logically additional 
studies on clustering patterns of other membrane proteins 
would be  necessary to prove or falsify that hypothesis, 
we  indicated that patterns of clustering of both SERT and 
5HT2A receptor could be  considered as putative biomarkers 
of therapeutic efficacy for MDD (Rivera-Baltanas et al., 2014).
As a possible limitation, we  acknowledge that all these 
studies were carried out in a relatively small number of patients 
and thereby should be  replicated in larger cohorts and also 
tested in a properly designed clinical trial.
ADDITIONAL STUDIES ON MEMBRANE 
PROTEIN CLUSTERING (MPC) IN 
LYMPHOCYTES IN AN ANIMAL MODEL 
OF DEPRESSION
In a very recent report, we  evaluated the patterns of clustering 
of multiple proteins in the repeated-corticosterone model of 
depression (Romay-Tallon et  al., 2018).
We centered our studies on proteins that tend to cluster 
into lipid rafts as alterations in G-protein-coupled receptor 
(GPCR) subunits integration into lipid rafts have been recently 
proposed as a putative mechanism of antidepressant actions 
(reviewed by Senese et  al., 2018). As mentioned above, our 
analyses indicated that changes in SERT and 5HT2A receptor 
MPC in the repeated-corticosterone model of depression paralleled 
those observed in depression patients (Romay-Tallon et  al., 
2018). We  also demonstrated that MPC patterns of SERT, 
5HT2AR, dopamine transporter, and NMDA receptor 2B subunit, 
indicate an increase in cluster size but not in cluster number, 
while MPC analysis of beta-adrenergic receptor 2 gives rise to 
A B C
FIGURE 2 | Schematic representation of SERT clusters in the membrane of lymphocytes from control (A) and depression patients (B,C). Analysis  
of SERT clustering in naïve depression patients allowed the differentiation of two subpopulations of depression patients (D-I and D-II) that primarily differ in the 
average size of SERT clusters. After 8 weeks of antidepressant treatment, there were no changes in SERT cluster number and size for D-I patients, but  
there was an increase in the number of SERT clusters in D-II patients (for more details see text, and Rivera-Baltanas et al., 2012).
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a decrease in receptor cluster size but no changes in numbers, 
and MPC study of pannexin 1 and prion cellular protein indicates 
that both the number and size of clusters are increased in the 
repeated-corticosterone model of depression (Romay-Tallon et al., 
2018). Thereby, this study indicated the feasibility of using 
animal models of depression both to study alterations in MPC 
in lymphocytes (including the design of novel studies focusing 
on mechanistic approaches) and to screen for additional patterns 
of MPC to be  further studied in MDD patients.
OTHER STUDIES DESIGNED TO 
FACILITATE TRANSLATION OF MPC 
STUDIES TO THE CLINICAL SETTING
Thinking about fostering the validation of MPC studies as a 
biomarker of therapeutic efficacy for MDD and how to bring 
those studies closer to the clinical setting, we  came to the 
realization that most diagnoses of MDD are first determined by 
family physicians in a family clinic and that collection of samples 
for MPC studies will be  much facilitated and also be  cheaper 
if those analyses could be  performed directly on blood smears 
instead that having a trained nurse drawing blood samples and 
then performing MPC studies on extracted lymphocytes as it 
was done for the studies mentioned in this review. Accordingly, 
we designed a comparative study of immunolabeling and analysis 
of MPC in extracted lymphocytes and in blood smears (Romay-
Tallon et  al., 2017) and were able to demonstrate that altering 
some parameters in fixation, incubation, and image analysis setting 
can result in similar measurements in MPC in whole blood 
drawn samples and in blood smears (Romay-Tallon et  al., 2017). 
One should also consider that proper establishment of fixation, 
incubation temperature and time, and image analysis protocols 
are essential for an adequate standardization of MPC analysis 
technologies (for a more detailed discussion see Rivera-Baltanas 
et  al., 2010 and Romay-Tallon et  al., 2017).
ADDITIONAL IDEAS AND EXPERIMENTS
The set of experiments discussed here clearly points to the 
interest of the MPC approach for developing of novel biomarkers 
of depression. Logically, this set of studies is complementary 
to the use of other technologies (i.e., “Omics,” neuroimaging, 
etc.) with the final intention of providing novel tools that 
result in a more precise approach to the use of the therapeutic 
arsenal for MDD treatment from a personalized 
medicine viewpoint.
We already mentioned the necessity of validating these 
studies in larger cohorts and in proper clinical trials. It is 
also a necessity to develop a way to perform automatic 
analyses of MPC that will facilitate the standardization for 
the technology and provide more accurate and 
faster measurements.
Next steps will logically involve the analysis in MPC 
patients of proteins that have been screened in animal models, 
as explained above, as this will also increase the efficacy of 
the test and the validation of the biomarker. It is also logic 
to think in using a similar approach for studies of other 
psychiatric disorders not only in terms of evaluating MPC 
as biomarkers of therapeutic efficacy but also of 
differential diagnoses.
Independently of research focusing on fostering MPC analyses 
as biomarkers of psychiatric disorders, there is also the necessity 
of developing mechanistic studies designed to evaluate how 
stress and depression bring about alterations in MPC in immune 
cells, what are the functional/pathological consequences of these 
alterations from a psychoneuroimmunology perspective, what 
are the mechanisms on antidepressant actions on MPC, and 
to evaluate if similar MPC alterations are also prevalent in 
the CNS and what would be the consequences of such changes. 
Finally, we can also surmise that these set of data may foster 
the idea of using MPC as a process to screen for antidepressant 
efficacy of novel compounds.
CONCLUSIONS
The data discussed in this review indicate the feasibility of 
analysis of MPC as a technology to develop novel biomarkers 
of therapeutic efficacy for MDD, which hopefully together with 
other biomarker technologies can result in a more efficacious 
use of current antidepressant drugs.
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